Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far?
Sign Up to like & getrecommendations! Published in 2020 at "European Archives of Oto-Rhino-Laryngology"
DOI: 10.1007/s00405-020-06003-w
Abstract: Background Cisplatin (CDDP) chemotherapy can cause serious side effects including irreversible and progressive hearing loss. Studies have aimed to assess potential protective strategies; however, systemic treatments have presented variable results, and potential interactions with CDDP… read more here.
Keywords: evaluating transtympanic; trials evaluating; transtympanic approach; cisplatin ... See more keywords
Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy113
Abstract: Background The first-line treatment of diffuse large B-cell lymphoma (DLBCL) is the combination of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, curing approximately 60% of patients. Many clinical trials have been carried out over… read more here.
Keywords: methodology; first line; trials evaluating; treatment ... See more keywords
Design of Phase II Oncology Trials Evaluating Combinations of Experimental Agents.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djad052
Abstract: We consider the design of phase II trials evaluating combinations of experimental therapies. In the modern era, many immunotherapy and targeted therapy regimens are being developed as combination regimens, including combinations consisting only of experimental… read more here.
Keywords: oncology; design phase; combination; evaluating combinations ... See more keywords